>>13818135The problem is getting rid of the pegylation once it crosses the BBB, and where they migrate to. LNPs even with an intramuscular delivery mechanism were a fucking mistake.
The exact formulation is not specified, but previous publications from Acuitas Therapeutics states that their LNPs are formulated using ionizable cationic lipids, phosphatidylcholine, cholesterol, and polyethylene glycol-lipid with a ratio of 0.05 of RNA to lipid (w/w). Similarly to Moderna, the exact lipids used were not stated.71 There is no indication that BioNTech/Pfizer utilizes an additional adjuvant with their vaccine although they do mention that the RNA acts as an adjuvant.
>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553041/>LNPs can undergo chemical and physical instability. Chemical instability comprises the degradation of the lipids in the LNPs that are susceptible to hydrolysis and oxidation. Lipid oxidation can occur in unsaturated fatty acid moieties (not present in Comirnaty and mRNA-1273) and with cholesterol, potentially as a result of a hydroperoxide attack, an impurity present in the PEG-group of PEG2000-C-DMG (Jaeger et al., 1994, Wang et al., 2019). Oxidative impurities may also result in oxidation of encapsulated mRNA. The carboxylic ester bonds in lipids, such as DSPC and the ionizable cationic lipids, are susceptible to temperature- and pH-dependent hydrolysis (Fig. 6 ).>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032477/So even assuming these people used neutral PEGylation methods to coat the LNPs, as I stated before these things do degrade, and when they do it's via oxidative cleavege, or general hydrolytic reactions. However when that happens, and if it just happens to happen in the BBB, there's going to be problems due to the cationic SM102 contents that encapsulate the mRNA payload.
